Skip to main content
Premium Trial:

Request an Annual Quote

New Website Launched to Support Lisp Programming Language

NEW YORK, Feb 6 – Advocates of the Lisp programming language for biological research announced Tuesday the launch of a new website, www.biolisp.org, to support those who are using or are interested in using Lisp.

Larry Hunter, director of the center for computational pharmacology and a member of the biolisp steering committee, said that the virtues of Lisp include: the ability to create high-level functions that are easily composed and allow for easy experimentations; an environment for building integrated databases and web servers; and full CORBA connectivity.

Such projects as EcoCyc, a database and software system used to manipulate the genome and study the metabolic pathways of E. coli , currently use Lisp code.

“Lisp gives us a powerful software development environment that lets our group efficiently maintain a large code base so we can focus our main efforts on our research,” Peter Karp, director of SRI International’s bioinformatics research group, said in a statement.

Russ Altman of Stanford Biomedical Informatics and Imran Shah of the University of Colorado School of Medicine are on the Lisp steering committee.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.